1 week Ago By Defense World Staff
Equities researchers at StockNews.com initiated coverage on shares of Cellectar Biosciences ( NASDAQ:CLRB – Get Free Report ) in a research note issued on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
A number of other research analysts also recently weighed in on CLRB. Oppenheimer reiterated a “market perform” rating on shares of Cellectar Biosciences in a report on Wednesday, December 11th. LADENBURG THALM/SH SH started coverage on Cellectar Biosciences in a research note on Thursday, December 5th.
They issued a “buy” rating and a $13.00 price target on the stock. Get Our Latest Stock Analysis on CLRB Cellectar Biosciences Stock Up 6.
3 % Cellectar Biosciences ( NASDAQ:CLRB – Get Free Report ) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter.
On average, analysts expect that Cellectar Biosciences will post -1.59 EPS for the current fiscal year. Institutional Investors Weigh In On Cellectar Biosciences Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock.
Rosalind Advisors Inc. raised its stake in Cellectar Biosciences by 35.7% during the 3rd quarter.
Rosalind Advisors Inc. now owns 3,671,550 shares of the biopharmaceutical company’s stock valued at $7,857,000 after buying an additional 965,934 shares during the last quarter. AIGH Capital Management LLC grew its holdings in shares of Cellectar Biosciences by 8.
2% in the second quarter. AIGH Capital Management LLC now owns 3,036,187 shares of the biopharmaceutical company’s stock worth $7,590,000 after acquiring an additional 231,270 shares during the period. XTX Topco Ltd increased its position in Cellectar Biosciences by 432.
4% during the second quarter. XTX Topco Ltd now owns 63,304 shares of the biopharmaceutical company’s stock valued at $158,000 after acquiring an additional 51,413 shares during the last quarter. Sequoia Financial Advisors LLC bought a new position in Cellectar Biosciences in the third quarter valued at about $51,000.
Finally, Oppenheimer & Co. Inc. purchased a new position in Cellectar Biosciences in the third quarter worth about $27,000.
Hedge funds and other institutional investors own 16.41% of the company’s stock. Cellectar Biosciences Company Profile ( Get Free Report ) Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer.
Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. Featured Articles Five stocks we like better than Cellectar Biosciences What is a SEC Filing? Quantum Opportunity: Skywater Technology’s Long-Term Potential How to Calculate Options Profits Nebius Group: The Rising Star in AI Infrastructure The 3 Best Blue-Chip Stocks to Buy Now MarketBeat Week in Review – 12/30 – 1/03 Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter .
.
